XenoPort Inc (XNPT)

7.07
0.05 0.71
Prev Close 7.02
Open 7.04
Day Low/High 7.02 / 7.07
52 Wk Low/High 3.35 / 7.86
Volume 2.62M
Avg Volume 1.64M
Exchange
Shares Outstanding 63.53M
Market Cap 449.13M
EPS -1.30
Div & Yield N.A. (N.A)
XenoPort To Present At Upcoming Healthcare Conferences

XenoPort To Present At Upcoming Healthcare Conferences

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentations at the RBC and Citigroup 2013 Healthcare Conferences.

XenoPort Announces New Employment Inducement Awards

XenoPort Announces New Employment Inducement Awards

XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to two new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.

XenoPort Announces New Employment Inducement Awards

XenoPort Announces New Employment Inducement Awards

XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to two new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.

XenoPort Announces New Employment Inducement Award

XenoPort Announces New Employment Inducement Award

XenoPort, Inc. (Nasdaq: XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.

XenoPort To Present At The 24th Annual Piper Jaffray Health Care Conference

XenoPort To Present At The 24th Annual Piper Jaffray Health Care Conference

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 24th Annual Piper Jaffray Health Care Conference.

XenoPort And GlaxoSmithKline Mutually Agree To Terminate Their Collaboration On Horizant

XenoPort And GlaxoSmithKline Mutually Agree To Terminate Their Collaboration On Horizant

XenoPort, Inc. (Nasdaq:XNPT) announced today that it has reached an agreement with Glaxo Group Limited (GSK) to terminate their collaboration agreement concerning Horizant® (gabapentin enacarbil) Extended-Release...

XenoPort Announces New Employment Inducement Award

XenoPort Announces New Employment Inducement Award

XenoPort, Inc. (Nasdaq: XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.

XenoPort To Present At The Credit Suisse Healthcare Conference

XenoPort To Present At The Credit Suisse Healthcare Conference

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2012 Credit Suisse Healthcare Conference.

XenoPort Reports Third Quarter Financial Results

XenoPort Reports Third Quarter Financial Results

XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2012.

XenoPort To Release Third Quarter Financial Results On October 24, 2012

XenoPort To Release Third Quarter Financial Results On October 24, 2012

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its third quarter financial results on October 24, 2012 at approximately 4:30 p.

8 Stocks Rising on Unusual Volume

8 Stocks Rising on Unusual Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

XenoPort Reports Favorable Metabolism And Pharmacokinetics Of XP23829, A Novel Fumaric Acid Ester, In Phase 1 Trial

XenoPort Reports Favorable Metabolism And Pharmacokinetics Of XP23829, A Novel Fumaric Acid Ester, In Phase 1 Trial

XenoPort, Inc. (Nasdaq: XNPT) announced today favorable preliminary results from a Phase 1 clinical trial in healthy adults designed to assess the pharmacokinetics (PK), safety and tolerability of single doses of four...

Lessons From Biotech's Best Third Quarter Stocks

Lessons From Biotech's Best Third Quarter Stocks

The biotech bubble grew in the third quarter, resulting in outsized gains for some unworthy stocks

XenoPort's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

XenoPort's CEO Presents At Morgan Stanley Healthcare Conference (Transcript)

XenoPort's CEO Presents at Morgan Stanley Healthcare Conference (Transcript)

XenoPort To Present At The Morgan Stanley Global Healthcare Conference

XenoPort To Present At The Morgan Stanley Global Healthcare Conference

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference.

8 Stocks Under $10 Surging Higher

8 Stocks Under $10 Surging Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Xenoport CFO Presents At Wedbush Securities Conference - Conference Call Transcript

Xenoport CFO Presents At Wedbush Securities Conference - Conference Call Transcript

Xenoport CFO Presents at Wedbush Securities Conference - Conference Call Transcript

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

XenoPort To Present At The Wedbush Life Sciences Conference

XenoPort To Present At The Wedbush Life Sciences Conference

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2012 Wedbush PacGrow Life Sciences Management Access Conference.

Xenoport's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Xenoport's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Xenoport's CEO Discusses Q2 2012 Results - Earnings Call Transcript

XenoPort Reports Second Quarter Financial Results

XenoPort Reports Second Quarter Financial Results

XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the second quarter and six months ended June 30, 2012.

Momentarily Curbing My Cynicism

If Friday's jobs data surprise to the upside, the market could rally on good news for a change.

XenoPort To Release Second Quarter Financial Results On August 7, 2012

XenoPort To Release Second Quarter Financial Results On August 7, 2012

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its second quarter financial results on August 7, 2012 at approximately 4:30 p.

7 Stocks Under $10 Surging Higher

7 Stocks Under $10 Surging Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

XenoPort Announces Pricing Of Public Offering Of Common Stock

XenoPort Announces Pricing Of Public Offering Of Common Stock

XenoPort, Inc. (Nasdaq:XNPT) announced today the pricing of an underwritten offering of 6,153,846 shares of its common stock at a price to the public of $6.

XenoPort Announces Proposed Public Offering Of Common Stock

XenoPort Announces Proposed Public Offering Of Common Stock

XenoPort, Inc. (Nasdaq: XNPT) announced today that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering.

XenoPort Announces Initiation Of A Phase 1 Clinical Trial Of XP23829, A Novel Fumarate Analog For The Potential Treatment Of Relapsing-Remitting Multiple Sclerosis And Psoriasis

XenoPort Announces Initiation Of A Phase 1 Clinical Trial Of XP23829, A Novel Fumarate Analog For The Potential Treatment Of Relapsing-Remitting Multiple Sclerosis And Psoriasis

XenoPort, Inc. (Nasdaq: XNPT) announced today that the first subjects have been dosed in a Phase 1, randomized, double-blind, two-period crossover, food effect comparison study of XP23829 in healthy adults.

XenoPort Awarded Grant From The Michael J. Fox Foundation To Examine XP23829 In Preclinical Models Of Parkinson’s Disease

XenoPort Awarded Grant From The Michael J. Fox Foundation To Examine XP23829 In Preclinical Models Of Parkinson’s Disease

XenoPort, Inc. (Nasdaq:XNPT) announced today that it has been awarded a grant from The Michael J.

Astellas And XenoPort Announce The Launch Of Regnite® Tablets For Restless Legs Syndrome In Japan

Astellas And XenoPort Announce The Launch Of Regnite® Tablets For Restless Legs Syndrome In Japan

Astellas Pharma Inc. (Tokyo: 4503) and XenoPort, Inc.

The Bounce Bruises the Shorts

Overbought can easily become more overbought, especially in low-volume holiday trading.